| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/04/2010 | WO2010013204A1 Composition for regenerating senescent cutaneous and sub-cutaneous tissue, products and uses thereof |
| 02/04/2010 | WO2010012777A1 THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| 02/04/2010 | WO2010012733A1 Use of a cdk inhibitor for the treatment of glioma |
| 02/04/2010 | WO2010012506A1 Cannabinoids for use in treating or preventing cognitive impairment and dementia |
| 02/04/2010 | WO2009150257A3 Compositions for treating rosacea comprising chitosan and a dicarboxylic acid |
| 02/04/2010 | WO2009103788A9 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 02/04/2010 | US20100029780 Topical composition |
| 02/04/2010 | US20100029755 P-Glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| 02/04/2010 | US20100029744 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement |
| 02/04/2010 | US20100029712 Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 02/04/2010 | US20100029673 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
| 02/04/2010 | US20100029600 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 02/04/2010 | US20100028905 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 02/04/2010 | US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 02/04/2010 | US20100028327 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/04/2010 | US20100028315 Dried and/or microencapsulated saccharomyces cerevisiae cells with a high content of (s)-(+)-s-adenosyl-l-methionine, process for their preparation, and compositons containing said cells |
| 02/04/2010 | US20100028308 Methods to maintain, improve and restore the cartilage phenotype of chondrocytes |
| 02/04/2010 | US20100028305 Methods for the treatment of lysosomal storage disorders |
| 02/04/2010 | DE20321786U1 Kombinationspräparat aus oralem Kontrazeptivum und Calcium/Vitamin D Combination preparation of oral contraceptive and calcium / vitamin D |
| 02/03/2010 | EP2149382A1 Dentinogenesis promoter and dentinogenic pulp-capping material |
| 02/03/2010 | EP2149376A1 Body-temperature lowering depressant |
| 02/03/2010 | EP2149372A1 Use of opioids or opioid mimetics for the treatment of resistant cancer patients |
| 02/03/2010 | EP1351679B1 Method and composition for the treatment of diabetic neuropathy |
| 02/03/2010 | CN101641117A Pharmaceutical composition |
| 02/03/2010 | CN101641116A Methods of treating cancer by administering human IL-18 combinations |
| 02/03/2010 | CN101637609A Drug composition containing amlodipine, A II receptor antagonist and statins |
| 02/03/2010 | CN100586481C Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/03/2010 | CN100586478C Solid tumor treating medicine composition |
| 02/03/2010 | CN100586477C Combined application of artemisinin and its derivative and antibiotic medicine |
| 02/02/2010 | US7655780 Integrin-linked kinase and its uses |
| 02/02/2010 | US7655771 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 02/02/2010 | US7655760 Antibodies to the polypeptide hormone phosphatonin |
| 02/02/2010 | US7655717 Ointment composition for treating decubitus ulcers and methods for its making and its use |
| 02/02/2010 | US7655676 Selective activity against propionibacterium acne; minimum inhibitory concentration (MIC) against Propionibacterium acnes strains both sensitive and resistant to erythromycin and clindamycin and against a series Staphylococcus strains |
| 02/02/2010 | US7655641 3-(4-{2-[(5-Fluoro-3- methyl-benzo[b]thiophene-2- sulfonyl)-propyl- amino]-ethylsulfanyl}- 2-methyl-phenyl)- propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, hypertension, arteriosclerosis and cardiovascular diseases |
| 02/02/2010 | US7655633 Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia |
| 02/02/2010 | US7655628 Method for treating liver cirrhosis or interstitial pulmonary fibrosis |
| 02/02/2010 | US7655616 Traumatic brain and spinal cord injury treatment; administering interleukin-1B converting enzyme (capsase-1) inhibitor |
| 02/02/2010 | US7655460 Nucleic acids encoding sodium channel SCN1A alpha subunit proteins with mutations associated with epilepsy |
| 02/02/2010 | US7655426 Ephrin-B receptor protein involved in carcinoma |
| 02/02/2010 | US7655425 Uses of a chemokine receptor able to bind to MCP-1, MIP-1α and/or RANTES |
| 02/02/2010 | US7655415 Interleukin 1 Receptor-Like 1 (IL1RL-1); cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure |
| 02/02/2010 | US7655408 PCA3 messenger RNA species in benign and malignant prostate tissues |
| 02/02/2010 | US7655398 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 02/02/2010 | US7655260 Antibiotic-free animal feed containing colloidal silver andfish cartilidge powder; health-promoting for livestock including mink, poultry and pigs; plasmacytosis, puppy disease, enteritis virus, three-day sickness and/or "sticky" kits in mink; immunocompetance; veterinary medicine |
| 02/02/2010 | US7655256 Pharmaceutical formulation including a resinate and an aversive agent |
| 02/02/2010 | US7655252 Antimicrobial nanoemulsion compositions and methods |
| 02/02/2010 | US7655242 Defensin-inducing agents |
| 02/02/2010 | US7654999 Tissue volume reduction |
| 02/02/2010 | US7654957 Apparatus for physical measurements of the eye |
| 02/02/2010 | CA2454830C Substituted urea neuropeptide y y5 receptor antagonists |
| 02/02/2010 | CA2442478C Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation |
| 02/02/2010 | CA2426043C Modulating angiogenesis |
| 02/02/2010 | CA2410305C Preparations comprising combinations of enzyme inhibitors, and the use thereof |
| 02/02/2010 | CA2360228C Treatment of tumor metastases and cancer |
| 02/02/2010 | CA2293724C Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 01/28/2010 | WO2010010985A1 Multi-layered lamellar granule and skin external application composition containing same |
| 01/28/2010 | WO2010010908A1 Therapeutic agent for migraine |
| 01/28/2010 | WO2010010797A1 Pharmaceutical composition comprising dyrk-inhibiting compound |
| 01/28/2010 | WO2010010702A1 Prophylactic or therapeutic agent for axial myopia |
| 01/28/2010 | WO2010009985A2 Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents |
| 01/28/2010 | WO2010009967A1 Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |
| 01/28/2010 | WO2010009618A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 01/28/2010 | WO2009136396A3 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| 01/28/2010 | WO2009090656A3 Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| 01/28/2010 | WO2009047826A8 Pharmaceutical composition comprising sucralphate and mesalazine |
| 01/28/2010 | WO2009024631A3 A combination of inhibitors of tgfbeta-1 and matrix metalloproteins for use in the treatment of bone metastases, bone resorption and hypercalcaemia |
| 01/28/2010 | WO2005062879A9 Canine probiotic bifidobacteria pseudolongum |
| 01/28/2010 | US20100022659 Methods and Compositions for the Treatment of CNS-Related Conditions |
| 01/28/2010 | US20100022651 Method For Increasing Hair Growth |
| 01/28/2010 | US20100022492 Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set |
| 01/28/2010 | US20100022474 Polymer Controlled Induced Viscosity Fiber System and Uses Thereof |
| 01/28/2010 | US20100021976 Production of polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs |
| 01/28/2010 | US20100021542 Extended release oral dosage composition |
| 01/28/2010 | US20100021524 Pimethixene derivatives for promoting bone growth |
| 01/28/2010 | US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control |
| 01/28/2010 | US20100021468 Novel mhc class ii restricted t cell epitopes from the cancer anitgen, ny eso-1 |
| 01/28/2010 | US20100021442 Method for promoting immunotherapy using an agent for elevating dendritic cell precursor level in blood |
| 01/28/2010 | US20100021433 Disease treatment via developing non-syngeneic graft transplantation |
| 01/28/2010 | US20100021432 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus |
| 01/28/2010 | US20100021402 Compounds, Formulations, and Methods for Ameliorating Telangiectasis |
| 01/28/2010 | CA2731573A1 Therapeutic agent for migraine |
| 01/27/2010 | EP2147679A2 Compositions and methods for modulating blood-brain barrier transport |
| 01/27/2010 | EP2147672A1 Cytotoxic t cell activator comprising ep4 agonist |
| 01/27/2010 | EP2146963A2 Dual-acting antihypertensive agents |
| 01/27/2010 | EP2146735A1 Sparc and methods of use thereof |
| 01/27/2010 | EP2146721A2 Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival |
| 01/27/2010 | EP2146581A2 Compositions and methods for cell killing |
| 01/27/2010 | EP2146573A1 Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists |
| 01/27/2010 | EP1830833B1 Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| 01/27/2010 | EP1732574B1 Use of o-atp for the treatment of diseases involving angiogenesis |
| 01/27/2010 | EP1562612B1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine for use in the treatment or prophlaxix of pancreatic cancer |
| 01/27/2010 | EP1343485B1 Drug delivery system comprising a lipid-based nitric oxide donor |
| 01/27/2010 | CN101636180A Peptide compounds for treating refractory status epilepticus |
| 01/27/2010 | CN101633646A Salts of valsartan |
| 01/27/2010 | CN101633636A Peptidomimetic protease inhibitors |
| 01/27/2010 | CN101632843A Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
| 01/27/2010 | CN101632663A Novel molecular target for neurotoxicity |
| 01/27/2010 | CN100584842C Thiazole derivative |
| 01/27/2010 | CN100584382C Medicinal composition containing angiotensin II receptor agonist and fibric acid compound |